Skip to main content
Clinical Trials/NCT06543173
NCT06543173
Recruiting
Not Applicable

Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator (PRIMARY PREVENT-VT TRIAL)

University of Rochester2 sites in 2 countries62 target enrollmentJanuary 22, 2026

Overview

Phase
Not Applicable
Intervention
Prophylactic Catheter-based VT Ablation
Conditions
Heart Failure
Sponsor
University of Rochester
Enrollment
62
Locations
2
Primary Endpoint
Total Number of VT Arrhythmia Events in High-Risk Patients with Ischemic Cardiomyopathy (ICM) After Primary ICD Implantation: Comparison of Preventive Catheter-Based VT Ablation Versus Medical Management.
Status
Recruiting
Last Updated
24 days ago

Overview

Brief Summary

This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.

Detailed Description

This study aims to assess the impact of prophylactic catheter-based ventricular tachycardia (VT) ablation compared to medical management in high-risk patients with ischemic cardiomyopathy (ICM) undergoing primary implantable cardioverter defibrillator (ICD) implantation. The primary outcome measure is the burden of VT arrhythmias (VTA), defined as the total number of VT events, one year post-ICD implantation. The hypothesis suggests that employing VT ablation with high-density electroanatomic mapping (EnsiteTM) will significantly reduce both treated and monitored VT episodes. The study will randomize 62 participants in a 1:1 ratio across 20 experienced sites in Europe.

Registry
clinicaltrials.gov
Start Date
January 22, 2026
End Date
August 1, 2030
Last Updated
24 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ilan Goldenberg

Ilan Goldenberg, MD, Professor of Medicine

University of Rochester

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years (no upper age limit)
  • Willing and able to provide informed consent
  • Candidate for a primary prevention ICD/CRT-D per ESC guidelines17
  • Ischemic cardiomyopathy (ICM) with left ventricular ejection fraction (LVEF) ≤ 35%
  • Willing and able to receive an ICD
  • Willing and able to undergo catheter-based VT ablation
  • One or more of the following:
  • MADIT-ICD Benefit Score \>75
  • History of nonsustained ventricular tachycardia (NSVT)
  • Multiple premature ventricular complexes (PVCs ≥10%)

Exclusion Criteria

  • Existing ICD or CRT-D
  • History of sustained VT or VF
  • Chronic renal failure requiring hemodialysis
  • Coronary revascularization within the past 3 months
  • ST-Elevation MI within the past 3 months
  • Participation in concurrent clinical trials without approval from the Coordination Center (observational registries are allowed with approval)
  • Currently pregnant or planning to become pregnant in the near future
  • Inability or unwillingness to adhere to the study protocol
  • Inability or unwillingness to provide informed consent for participation
  • Life expectancy \< 1 year

Arms & Interventions

Prophylactic Catheter-based VT Ablation

Subjects receive catheter-based ventricular tachycardia (VT) ablation within 3 months of primary ICD implantation.

Intervention: Prophylactic Catheter-based VT Ablation

Continued Medical Management

Subjects undergo continued medical management after primary ICD implantation without prophylactic VT ablation.

Outcomes

Primary Outcomes

Total Number of VT Arrhythmia Events in High-Risk Patients with Ischemic Cardiomyopathy (ICM) After Primary ICD Implantation: Comparison of Preventive Catheter-Based VT Ablation Versus Medical Management.

Time Frame: One year following ICD implantation.

Evaluating the impact of preventive catheter-based VT ablation versus medical management on the total number of VT arrhythmia events in high-risk patients with ischemic cardiomyopathy (ICM) after primary ICD implantation.

Secondary Outcomes

  • Impact of Preventive VT Ablation on Healthcare Utilization, assessed using the mean rate of events per arm.(One year following ICD implantation.)

Study Sites (2)

Loading locations...

Similar Trials